Innovent Biologics , a multinational biopharmaceutical company, and Eli Lilly and Company presented their co-developed Tyvyt® , a fully human anti-programmed cell death protein 1 monoclonal antibody at CIIE 2019. The medicine works to block the interaction of PD-1 with its ligands and consequently help patients restore the endogenous anti-tumour T-cell response. The new medical breakthrough, the result of the cooperation between the two companies, provides global patients with a more effective, safer treatment solution to fight cancer.
The world-leading anti-PD-1 inhibitor, Tyvyt® has been granted approval for market authorization by the National Medical Products Administration of China ("NMPA", formerly the China Food and Drug Administration) for the treatment of patients with classical cHL or relapsed or refractory r/r cHL Hodgkin's lymphoma following two or more lines of systemic chemotherapy. It also has been selected into the Guidelines of Chinese Society of Clinical Oncology (CSCO) for Lymphoid Malignancies in 2019. Sintilimab injection is currently undergoing 20 clinical studies, 8 of which are registered clinical trials, to explore its application for a variety of solid tumors.
To push the boundaries of global cooperation, Innovent Biologics established a strategic alliance with Eli Lilly and Company covering research, registration, production and market development, helping Chinese medical institutes to bring in new concepts on the journey to going global.
"International cooperation is one of the founding principles and core strategies of Invent biologics. The cooperation with Eli Lilly and Company in the field of cancer and diabetes is a testimony to our pursuit and efforts to build an international platform to create the best-in-class treatment for global patients," said Min Liu, Chief Business Officer of Innovent Biologics. "It is on this platform that we hope more excellent medical products can be introduced to China so patients can enjoy the benefits of Chinese scientific studies and significant medical findings globally."
Innovent Biologics has formed a groundbreaking biotech drug development collaboration with Eli Lilly since 2015. In the joint efforts to address the growing burden of cancer, the two companies are set to collaborate on the development and commercialization of at least three sintilimab-based cancer treatments over the next decade.
In August 2019, Innovent entered into a licensing agreement with Eli Lilly and Company for the development and commercialization of oxyntomodulin analog, OXM3. It has entered China as a first-in-class dual GLP-1 and glucagon receptor agonist which is currently undergoing mid-stage clinical development. As part of a new partnership for developing the next-generation drugs of cancer immunotherapy, Eli Lilly is leading medical research and working with Innovent to introduce high-quality and affordable cancer-fighting products to China's market.
Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to develop and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality, innovative medicines for the treatment of oncology, autoimmunity and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
SOURCE Innovent Biologics, Inc.
Innovation Biologics ，一家跨国生物制药公司，礼来（Eli Lilly） and Company 在 CIIE 2019上展示了他们共同开发的 Tyvyt ®，一种全人抗程序性细胞死亡蛋白1单克隆抗体。该药物致力于阻断 PD-1与其配体的相互作用，从而帮助患者恢复内源性抗肿瘤 T 细胞反应。新的医疗突破，是两家公司合作的结果，为全球患者提供了更有效、更安全的治疗方案来对抗癌症。
全球领先的抗 PD-1抑制剂 Tyvyt ®已获得中国国家医疗产品管理局（ NMPA ）的市场授权。原中国食品药品监督管理总局）用于治疗经典 cHL 或复发或难治性 r / r cHL 霍奇金淋巴瘤，经过两条或两条以上的系统化疗。它还入选了中国临床肿瘤学会（ CSCO ）关于2019年淋巴瘤恶性的指南。Sintilmab 注射液目前正在进行20项临床研究，其中8项为注册临床试验，以探索其应用于多种实体瘤。
为推进全球合作的边界， Innovation Biologics 与礼来（Eli Lilly）公司建立了战略联盟，涵盖研究、注册、生产和市场开发，帮助中国医疗机构在走向全球的道路上引入新的理念。
国际合作是生物技术创新的基本原则和核心战略之一。与礼来（Eli Lilly）公司在癌症和糖尿病领域的合作证明了我们的追求和努力，以建立一个国际平台，为全球患者创造一流的治疗，” Innovate Biologics 首席商务官 Min Liu 说。“正是在这个平台上，我们希望能将更多优秀的医疗产品引入中国，让患者享受中国科学研究和全球重大医学发现的益处。”
Innovative Biologics 自2015年起与礼来（Eli Lilly）公司形成了突破性的生物技术药物研发合作。在共同努力解决日益增长的癌症负担方面，这两家公司将在未来十年内合作开发和商业化至少三种基于烧结的癌症治疗方法。
2019年8月， Innovent 与礼来（Eli Lilly） and Company 签订了一项许可协议，用于开发和商业化氧同模素类似物 OXM3。已进入中国，成为目前正在进行中期临床开发的一级双效 GLP-1和胰高血糖素受体激动剂。作为开发新一代肿瘤免疫治疗药物的新伙伴关系的一部分，礼来（Eli Lilly）公司是领先的医学研究机构，与 Innovent 公司合作，向中国市场推出高质量、价格合理的抗癌产品。
本着“以诚信为先，以行动成功”的精神， Innovant 的使命是开发和商业化普通百姓都能负担得起的优质生物制药产品。Innovation 成立于2011年，致力于研发、制造和商业化治疗肿瘤、自身免疫等重大疾病的优质、创新药物。2018年10月31日， Innovation 在香港联合交易所有限公司主板上市，股票代码：01801。香港。
SOURCE Innovate Biologics , Inc .